A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AZR-MD-001 in Patients with Meibomian Gland Dysfunction (MGD) and Evaporative Dry Eye Disease (DED).

Trial Information

Start DateJanuary 2022
End DateJanuary 2023
Trial Duration6 months
Number of Visits7
StatusIn Recruitment

For additional information
on this trial contact: